0.01
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Eastgate Biotech
Its shares trade under the ticker ETBI. It has been listed since 16 January 2014. In the fiscal year to 31 December 2015, it reported revenue of $132,025 and a net loss of $4.3m. At that date it held total assets of $297,919 and shareholders' equity of −$2.5m.
Eastgate Biotech Corp. engages in the development of novel formulations of natural compounds and pharmaceutical products. The company is headquartered in Salt Lake City, Utah. The company went IPO on 2014-01-16. The firm is primarily engaged in the development of formulations of natural compounds and pharmaceutical products. The firm produces and distributes healthy nutraceuticals that are based on natural therapies and absorbed naturally by the body. The firm offers EGP-1214, a compressed tablet containing human recombinant insulin that is designed for sublingual administration. The company offers a range of products, such as E-Drops, which is used to combat urinary and vaginal tract infections; Essential D, which is an enhanced Vitamin D3, working to improve the body's digestive, cardiovascular, and immune systems; Puralen, is an all-natural herbal cleanse of colon and the urinary tract; GluCora, which prevents fat deposition; VCleanzz, which is an antibacterial wash for fruits and vegetables; Cleanezze, which is a natural hand sanitizer, and Warts X, which is a natural herbal product that treats warts.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 16 Jan 2014
- Website
- eastgatebiotech.com ↗
Leadership
Pay as last reported
- Ms. Rose PerriPresident, Treasurer, Secretary, Director, since 2015$250,000
- Ms. Anna GluskinChief Executive Officer, Director, since 2012$300,000
- Mr. Bill AbajianChief Operating Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Innovative Products: Eastgate Biotech Corp offers a range of unique and innovative biotechnology products, giving them a competitive edge in the market.
- Strong Research and Development: The company has a dedicated team of scientists and researchers, consistently working on developing new products and improving existing ones.
- Solid Financial Position: Eastgate Biotech Corp has a stable financial position, allowing them to invest in research, marketing, and growth opportunities.
Weaknesses
- Limited Market Presence: The company currently has a limited market presence and brand recognition, which makes it challenging to compete with established competitors.
- Reliance on Third-Party Suppliers: Eastgate Biotech Corp relies on third-party suppliers for key ingredients and materials, which can potentially disrupt the supply chain and impact product availability.
- Lack of Diversification: The company's product portfolio is focused on biotechnology products only, lacking diversification into other industries or sectors.
Opportunities
- Growing Demand for Biotechnology: The global biotechnology market is experiencing significant growth, providing Eastgate Biotech Corp with opportunities to expand its customer base.
- Strategic Partnerships: Collaborating with established pharmaceutical companies or institutions can help Eastgate Biotech Corp leverage their expertise, widen its distribution network, and gain credibility.
- Emerging Markets: Expanding into emerging markets where there is a rising demand for biotech products can help the company tap into new revenue streams.
Threats
- Intense Competition: The biotechnology industry is highly competitive, with numerous players vying for market share. Eastgate Biotech Corp faces the risk of competitors launching similar or superior products.
- Regulatory Challenges: The biotech industry is subject to stringent regulations and compliance requirements, which can pose hurdles and delays in product development and commercialization.
- Technological Advancements: Rapid advancements in biotechnology and genetic engineering may render current products obsolete or less effective, necessitating continuous innovation and adaptation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.